JP2022544216A5 - - Google Patents

Info

Publication number
JP2022544216A5
JP2022544216A5 JP2022507901A JP2022507901A JP2022544216A5 JP 2022544216 A5 JP2022544216 A5 JP 2022544216A5 JP 2022507901 A JP2022507901 A JP 2022507901A JP 2022507901 A JP2022507901 A JP 2022507901A JP 2022544216 A5 JP2022544216 A5 JP 2022544216A5
Authority
JP
Japan
Prior art keywords
acid
composition according
aqueous solution
solution composition
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022507901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544216A (ja
Filing date
Publication date
Priority claimed from GBGB1911461.0A external-priority patent/GB201911461D0/en
Application filed filed Critical
Publication of JP2022544216A publication Critical patent/JP2022544216A/ja
Publication of JP2022544216A5 publication Critical patent/JP2022544216A5/ja
Pending legal-status Critical Current

Links

JP2022507901A 2019-08-09 2020-08-07 抗体を含む新規組成物 Pending JP2022544216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1911461.0A GB201911461D0 (en) 2019-08-09 2019-08-09 Novel composition
GB1911461.0 2019-08-09
PCT/GB2020/051900 WO2021028669A1 (en) 2019-08-09 2020-08-07 Novel composition comprising antibodies

Publications (2)

Publication Number Publication Date
JP2022544216A JP2022544216A (ja) 2022-10-17
JP2022544216A5 true JP2022544216A5 (https=) 2023-08-15

Family

ID=67874470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507901A Pending JP2022544216A (ja) 2019-08-09 2020-08-07 抗体を含む新規組成物

Country Status (11)

Country Link
US (2) US20220288165A1 (https=)
EP (1) EP4010365A1 (https=)
JP (1) JP2022544216A (https=)
KR (1) KR20220044761A (https=)
CN (3) CN114206391B (https=)
AU (1) AU2020328218A1 (https=)
CA (1) CA3144885A1 (https=)
GB (1) GB201911461D0 (https=)
IL (1) IL290300A (https=)
MX (1) MX2022001687A (https=)
WO (1) WO2021028669A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005170A (es) 2017-11-17 2020-10-16 Amgen Inc Formulaciones de proteinas de fusion vegfr-fc.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
CN102066401A (zh) * 2008-05-01 2011-05-18 艾瑞克有限公司 蛋白质制品
CA2738243C (en) * 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
CN103358715B (zh) * 2012-03-30 2016-12-14 山东新北洋信息技术股份有限公司 出纸模块的识别方法、出纸模块、打印机以及打印系统
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
WO2015080513A1 (en) * 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
JP2019529506A (ja) * 2016-09-29 2019-10-17 アレコル リミテッド 新規の製剤
PT3528787T (pt) * 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
JP7116059B2 (ja) * 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
GB201703063D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions

Similar Documents

Publication Publication Date Title
CN102946858B (zh) 含有免疫球蛋白Fc的多肽的液体制剂
JP7374953B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
Cross et al. N-terminal deletions in Rous sarcoma virus p60 src: effects on tyrosine kinase and biological activities and on recombination in tissue culture with the cellular src gene
JP7536640B2 (ja) ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤
CA2674765A1 (en) Stabilization of aqueous compositions of proteins with displacement buffers
EP3496755A1 (en) Tgf- antagonist conjugates
JP2022544216A5 (https=)
CN111511351A (zh) 新型组合物
CN116368224A (zh) Ace2突变蛋白及其使用方法
CN102482341A (zh) 纯化vwf以增加非-脂质包封的病毒的去除
NZ508317A (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
US20130183330A1 (en) Recombinant avian infectious coryza vaccine and process for preparing same
JP2024507347A5 (https=)
WO2023164898A1 (zh) 一种重组融合蛋白的制剂
RU2022105796A (ru) Новая композиция, содержащая антитела
Chang et al. Commercial antithrombin concentrate contains inactive L-forms of antithrombin
CN114206391B (zh) 包含抗体的新组合物
JP6383721B2 (ja) 創傷治癒剤
JP2024506718A5 (https=)
Hu et al. Functional significance of alternate phosphorylation in Sendai virus P protein
JP2024506718A (ja) 工学作成二量体タンパク質の安定性を高めるための水溶液組成物
EP4028542A1 (en) Compositions, methods, and kits for detection of lipolytic activity
Malferrari et al. Molecular characterization of a novel endonuclease (Xib) and possible involvement in lysosomal glycogen storage disorders
TW202528339A (zh) 用於治療或預防肝臟病症之骨髓源性生長因子
RU2395582C2 (ru) СПОСОБ РАСЩЕПЛЕНИЯ ПОЛИПЕПТИДОВ С ИСПОЛЬЗОВАНИЕМ ВАРИАНТА ПРОТЕАЗЫ ОmpТ